ArticleF1000Research2025
A Preclinical Model of Human Liver Using Precision Cut Tissue Slice Culture.
Article in F1000Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- When Liver Slices Meet Single-cell Technology.Cellular and molecular gastroenterology and hepatology · 2026Article
- Targeting the tumor microenvironment in cholangiocarcinoma to improve immune checkpoint blockade: potential strategies and translational pre-clinical models.Clinical & translational immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preclinical models vary in complexity and cost. Traditional 2D cell cultures that are high throughput and cost effective, but lack the complexity of multicellular interactions. Animal models and more complex, but are costly, raise ethical concerns and are not a human model to better understand human disease or response to novel treatments. Human precision cut tissue slice (hPCTS) models bridge this gap, maintaining the architecture and microenvironment of original tissues. This study examines the viability and functionality of hPCTS using different tissue culture formats. Previous studies have cultured hPCTS with gentle agitation, either on an insert or floating in tissue culture medium. More recently the use of a proprietary flow system for hPCTS culture has been explored, aiming to provide a more physiologically relevant environment. CELLBLOKS® provide a commercially available flow system platform designed for cell culture that we adapted to accommodate hPCTS. hPCTS were cultured for 15 days using an organotypic polytetrafluoroethylene Millicell insert, a CELLBLOKS® hydrophilic polyethylene terephthalate flow system plate or without an insert. Viability was assessed through MTS assays, while functionality was determined by measuring urea and albumin secretion across the 15 days in culture. The Millicell inserts maintained higher and more consistent viability and functionality over 15 days. Slices cultured with no inserts showed decreased viability and functionality after 7 days in culture. In contrast, CELLBLOKS® cultured hPCTS showed significantly decreased viability and function after 3 days in culture. This study suggests that while the CELLBLOKS® system shows promise for 2D cell line cultures, Millicell Biopore™ inserts offer a more reliable method for maintaining complex hPCTS cultures, preserving both viability and function. As a viable, human-specific alternative to animal models, hPCTS support the 3Rs and have the potential to reduced and potentially replace the use of animals in preclinical research, improving human disease modelling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.